Benefit/risk profile of dapagliflozin 5 mg in theDEPICT-1 and-2 trials in individuals with type 1 diabetes and body mass index >= 27 kg/m(2)

Mathieu, Chantal; Dandona, Paresh; Birkenfeld, Andreas L.; Hansen, Troels Krarup; Iqbal, Nayyar; Xu, John; Repetto, Enrico; Scheerer, Markus Florian; Thoren, Fredrik; Phillip, Moshe

dc.contributor.author	Birkenfeld, Andreas L.
dc.date.accessioned	2020-12-15T11:57:09Z
dc.date.available	2020-12-15T11:57:09Z
dc.date.issued	2020
dc.identifier.issn	1463-1326
dc.identifier.uri	http://hdl.handle.net/10900/110705
dc.language.iso	en	de_DE
dc.publisher	Wiley	de_DE
dc.relation.uri	http://dx.doi.org/10.1111/dom.14144	de_DE
dc.subject.ddc	610	de_DE
dc.title	Benefit/risk profile of dapagliflozin 5 mg in theDEPICT-1 and-2 trials in individuals with type 1 diabetes and body mass index >= 27 kg/m(2)	de_DE
dc.type	Article	de_DE
utue.quellen.id	20200929220116_00205
utue.personen.roh	Mathieu, Chantal
utue.personen.roh	Dandona, Paresh
utue.personen.roh	Birkenfeld, Andreas L.
utue.personen.roh	Hansen, Troels Krarup
utue.personen.roh	Iqbal, Nayyar
utue.personen.roh	Xu, John
utue.personen.roh	Repetto, Enrico
utue.personen.roh	Scheerer, Markus Florian
utue.personen.roh	Thoren, Fredrik
utue.personen.roh	Phillip, Moshe
dcterms.isPartOf.ZSTitelID	Diabetes Obesity & Metabolism	de_DE
utue.fakultaet	04 Medizinische Fakultät	de_DE